Amgen

YTD

ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

31,500

Employees31,500

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

31,500

Employees31,500

AMGN Key Statistics

Market cap

188.79B

Market cap188.79B

Price-Earnings ratio

24.51

Price-Earnings ratio24.51

Dividend yield

2.77%

Dividend yield2.77%

Average volume

2.95M

Average volume2.95M

High today

$352.66

High today$352.66

Low today

$348.13

Low today$348.13

Open price

$351.83

Open price$351.83

Volume

805.83K

Volume805.83K

52 Week high

$391.29

52 Week high$391.29

52 Week low

$261.43

52 Week low$261.43

Stock Snapshot

Amgen(AMGN) stock is priced at $350.21, giving the company a market capitalization of 188.79B. It carries a P/E multiple of 24.51 and pays a dividend yield of 2.8%.

As of 2026-03-30, Amgen(AMGN) stock has fluctuated between $348.13 and $352.66. The current price stands at $350.21, placing the stock +0.6% above today's low and -0.7% off the high.

Amgen(AMGN) shares are trading with a volume of 805.83K, against a daily average of 2.95M.

During the past year, Amgen(AMGN) stock moved between $261.43 at its lowest and $391.29 at its peak.

AMGN News

Investor's Business Daily 4h

Why This Amgen Rival Just Plummeted By A Third - Investor's Business Daily

...

The Motley Fool 7h

This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks

The Schwab U.S. Dividend Equity ETF (SCHD 0.59%) has a very simple strategy. It tracks an index that aims to hold the top 100 high-yielding dividend stocks. Tha...

TipRanks 1d

Amgen announces data on Repatha from Phase 3 Vesalius-CV trial

Amgen (AMGN) announced that Repatha, when added to statins or other low-density lipoprotein cholesterol-lowering treatments, reduced the risk of first major adv...

Analyst ratings

53%

of 38 ratings

Buy

39.5%

Hold

52.6%

Sell

7.9%

More AMGN News

Simply Wall St 2d

Amgen’s Repatha Data Reinforces Cardiovascular Franchise And Valuation Debate

Amgen (NasdaqGS:AMGN) released new VESALIUS-CV Phase 3 subgroup data on Repatha showing a significant reduction in first major cardiovascular events in high ris...

Simply Wall St 3d

Assessing Amgen Valuation As Shares Show Mixed Short And Long Term Returns

Advertisement What Amgen’s Recent Share Moves Signal for Investors Amgen (AMGN) has seen mixed recent returns, with gains over the past year but a decline ove...

TipRanks 5d

Amgen’s Rocatinlimab Trial Completion Signals Next Phase for Atopic Dermatitis Strategy

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) has reported a key update on its Phase 3 ROCKET-Outpost study, which lo...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.